Pharmaceutical research and development (R&D) has skyrocketed in recent years and is projected to reach even greater levels in the future. The total R&D spending has increased by 33 billion…
Category: Pharmaceutical Drugs
in Access to Medicines, Blogs, Commercialization, Development, Innovation, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
490
Broken Promises: Utility Standards and Patent Applications in Canada
The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…
in Access to Medicines, Commercialization, Design, Development, IP, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
577
What Makes It My Molecule: A Look at Professor Ronald Pearlman’s Genome Editing Work
This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…
Bringing Biologics in from the Cold: Does Canada’s IP Regime Need a Booster?
As ratification stutters for the Comprehensive Economic and Trade Agreement (CETA), the much-maligned free-trade deal between Canada and the European Union, debate continues as to whether the Canadian intellectual property…
Pharmaceuticals Main Attraction in TPP IP Chapter
Patent law can be a polarizing topic, but it is especially so during international trade negotiations. Perhaps this is because the principles of patent law create fundamental conflicts between those…
The Not-So-Obvious Aspects of an Obviousness-Type Double Patenting Analysis
The granting of a patent has often been described as a bargain [1] between the government and the patentee. In exchange for the exclusive right [2] to make, construct, use…